These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34074778)

  • 21. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
    Granot T; Yamanashi Y; Meruelo D
    Mol Ther; 2014 Jan; 22(1):112-22. PubMed ID: 24025748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity.
    Roex MCJ; Hageman L; Veld SAJ; van Egmond E; Hoogstraten C; Stemberger C; Germeroth L; Einsele H; Falkenburg JHF; Jedema I
    Blood; 2020 Jul; 136(4):455-467. PubMed ID: 32483595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
    Poncette L; Chen X; Lorenz FK; Blankenstein T
    J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.
    Horiuchi Y; Takagi A; Uchida T; Akatsuka T
    Oncol Rep; 2015 Dec; 34(6):2827-36. PubMed ID: 26398429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
    van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
    Neal ZC; Bates MK; Albertini MR; Herweijer H
    Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH.
    Crowley SJ; Bruck PT; Bhuiyan MA; Mitchell-Gears A; Walsh MJ; Zhangxu K; Ali LR; Jeong HJ; Ingram JR; Knipe DM; Ploegh HL; Dougan M; Dougan SK
    Open Biol; 2020 Feb; 10(2):190235. PubMed ID: 32019478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.
    Soto CM; Stone JD; Chervin AS; Engels B; Schreiber H; Roy EJ; Kranz DM
    Cancer Immunol Immunother; 2013 Feb; 62(2):359-69. PubMed ID: 22926060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
    J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
    Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
    J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Antitumor Effects of Vaccine-Activated CD8
    Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y
    Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
    Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
    Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heteroclitic immunization induces tumor immunity.
    Dyall R; Bowne WB; Weber LW; LeMaoult J; Szabo P; Moroi Y; Piskun G; Lewis JJ; Houghton AN; Nikolić-Zugić J
    J Exp Med; 1998 Nov; 188(9):1553-61. PubMed ID: 9802967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Iero M; Filipazzi P; Castelli C; Belli F; Valdagni R; Parmiani G; Patuzzo R; Santinami M; Rivoltini L
    Cancer Immunol Immunother; 2009 Jul; 58(7):1159-67. PubMed ID: 18998128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.
    Taborska P; Stakheev D; Strizova Z; Vavrova K; Podrazil M; Bartunkova J; Smrz D
    Med Oncol; 2017 Sep; 34(10):173. PubMed ID: 28866803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
    Hiroishi K; Eguchi J; Baba T; Shimazaki T; Ishii S; Hiraide A; Sakaki M; Doi H; Uozumi S; Omori R; Matsumura T; Yanagawa T; Ito T; Imawari M
    J Gastroenterol; 2010 Apr; 45(4):451-8. PubMed ID: 19936602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.